Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478227 · ClinicalTrials.gov registry record · Early Phase 1
TPO-Mimetic Use in Children for Hematopoietic Failure
A Early Phase 1 study of Aplastic Anemia and Thrombocytopenia, sponsored by Anjali Sharathkumar.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04478227 is a Early Phase 1 study of Aplastic Anemia and Thrombocytopenia that has completed, run by Anjali Sharathkumar. The registered enrollment target is 15 participants, below the 42-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04478227, a Early Phase 1 study of Aplastic Anemia and Thrombocytopenia, has completed, sponsored by Anjali Sharathkumar.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.
Conditions Studied
Interventions
- DRUG Romiplostim
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2024-01-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04478227
The ClinicalTrials.gov registry entry for NCT04478227 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (64% lower). The listed sponsor is Anjali Sharathkumar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Romiplostim is the first listed.
NCT04478227 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04478227 about?
NCT04478227 is a clinical study titled "TPO-Mimetic Use in Children for Hematopoietic Failure". This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of ther...
What is the current status of trial NCT04478227?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2020-08-18. Estimated completion is 2024-01-18.
What conditions does trial NCT04478227 study?
This clinical trial studies the following conditions: Aplastic Anemia, Thrombocytopenia, Myelodysplastic Syndrome(MDS), Bone Marrow Failure Disorders, Refractory Cytopenia of Childhood.
What interventions are being tested in trial NCT04478227?
The interventions under investigation include: Romiplostim (DRUG).
Who is sponsoring clinical trial NCT04478227?
This trial is sponsored by Anjali Sharathkumar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04478227 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Umbilical Cord Blood Transplantation From Unrelated Donors
RECRUITING
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.